StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update
TORONTO, ON / ACCESSWIRE / November 15, 2023 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, today announced its third quarter financial results for the three and nine months ended September 30, 2023, and will provide an update on its business operations.
The Company has been building partnerships to broaden its reach and market penetration:
- agreement reached with major cancer centers in Toronto to study Aristotle in a clinical setting.
- METRICS II prospective Glioblastoma study designed; prospective UK/North America clinical study.
- CareOncology partnered with The Source Functional Nutrition group to add a third pillar to the cancer care setting - nutritional guidance for cancer patients.
- CareOncology partnered with the Wellness.Script to add a fourth pillar to the cancer care setting - mental health support.
- On November 14, 2023 the Company announced a partnership with My One Medical Source ("MOMS") to offer the StageZero suite of diagnostics and treatment protocols to MOMS' national customer base.
- MOMS has over 1,000 Medical Access Points ("MAPS") across the USA and connects providers, employers and patients with clinical laboratories. It instantly establishes a national patient service center network for StageZero and CareOncology and takes the Company's high complexity lab and makes it into 50 State local labs with all of the attendant customer base. MOMS will actively promote StageZero's diagnostic programs. This is supported by CareOncology clinic's physician oversight and telehealth network.
"A productive three to four months" said James Howard-Tripp, Chairman & CEO of StageZero Life Sciences. "We have been building out the systems and putting partnerships in place to increase our footprint and reach. Our major focus is on self-funded employers where we believe Aristotle and AVRT uniquely position us, but also with the insurance groups that back them. Of key importance, too, is a Direct to Consumer ("DTC") approach to individual patients who are playing a larger and larger role in how they direct their healthcare spend. Our partners reflect this" he added.
Operational Update: further details will be provided during the Analyst Call.